Lonza Group AG (SWX: LONN) is a Swiss contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotech industries. Specializing in biologics, cell and gene therapies, and small molecule APIs, Lonza plays a critical role in scaling complex therapies. With long-term client contracts and global facilities, the company benefits from rising biotech outsourcing and specialty medicine demand. Lonza offers investors a high-quality life sciences supplier with resilient, innovation-led growth.
最新股票文章

平頭哥分拆上市分析:阿里巴巴AI芯片業務的結構性風險與估值框架
阿里巴巴旗下平頭哥半導體擬分拆獨立上市,摩根大通估值介於250億至620億美元。本文從業務依賴度、估值方法論、地緣政策風險及港股科技板塊估值溢價等維度,解構該交易的結構性風險與分析框架。
14:16, 11 3月 2026


